Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
77.87 (1y: +35%)
Market Cap 17.45 B P/E(ttm)
Enterprise Value 16.95 B P/B 17.30
VRTX- NAS (USA)
Vertex Pharmaceuticals
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$77.87
Switch to:
Jump to: Guru Trade | Guru Ownership | Insider Trade

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M17,446Revenue $M1,417Net Margin (%)-7.0Z-Score4.8
Enterprise Value $M16,947EPS $-2.4Operating Margin %0.2F-Score2
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-0.8Higher ROA y-yN
Price/Book17.310-y EBITDA Growth Rate %0Quick Ratio3.1Cash flow > EarningsY
Price/Sales11.85-y EBITDA Growth Rate %0Current Ratio4.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-227.8ROA % (ttm)-3.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-10.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M218ROI % (ttm)20.8Gross Margin Increase y-yN

Gurus Latest Trades with VRTX

Please Subscribe to see portfolio changes after the end of the last quarter. Real Time Picks are included for Premium Members only! Plans start from as little as $299/year.

7-Day FREE TRIAL
Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus
Number of guru portfolios checked: 51.
TickerDate Action
 Impactdown Price Range
(Average)* 		Current Price Change from Average Comment Current Shares
VRTX2012-12-31 Sold Out -0.77%$38.88 - $59.42
($46.08)		 $ 77.8769%Sold Out0
VRTX2012-09-30 Add0.22%$48.38 - $59.07
($53.5)		 $ 77.8746%Add 40%700,000
VRTX2012-06-30 Buy 0.85%$35.75 - $65.62
($50.92)		 $ 77.8753%New holding, 500000 sh.500,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.
Total Records: 3

VRTX is held by these Gurus:

Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus
Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRTX Vanguard Health Care Fund 2013-03-312,489,8001.140.54+10.97%
Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2013-06-12Sell1,400$81.19-2.94view
BOGER JOSHUA SDirector 2013-06-05Sell1,400$77.152.14view
BOGER JOSHUA SDirector 2013-05-30Sell1,400$82.47-4.45view
BOGER JOSHUA SDirector 2013-05-22Sell1,400$79.72-1.15view
SACHS BRUCE IDirector 2013-05-22Sell8,300$79.77-1.22view
Stamoulis ChristianaSVP, Corp Strategy & Bus Devlp 2013-05-15Sell602$79.65-1.07view
BOGER JOSHUA SDirector 2013-05-15Sell1,400$79.36-0.71view
Silva Paul MSVP & Corp Controller 2013-05-15Sell609$79.66-1.08view
SMITH IAN FEVP & CFO 2013-05-15Sell609$79.67-1.09view
SACHS BRUCE IDirector 2013-05-14Sell60,000$81.15-2.9view

Press Releases about VRTX :

Quarterly/Annual Reports about VRTX:

News about VRTX:

Articles On GuruFocus.com
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
Vertex Could Climb On New Drug, VX-222 Success Apr 21 2012 
Achillion Will Surge If New Drug Is Successful Apr 21 2012 
Columbia Management Fourth Quarter Letter with Comments on SWK, AGCO, CE, MCP, VRTX, DOLE, F, HAS, A Apr 10 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
4 Pharmaceuticals with Long and Short Opportunities Feb 28 2012 
Hussman Fund Q4 Portfolio Overview Feb 02 2012 


Add Notes, Comments or Ask Questions

Please log in first

Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK